These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9860926)

  • 21. P450 active site architecture and reversibility: inactivation of cytochromes P450 2B4 and 2B4 T302A by tert-butyl acetylenes.
    Blobaum AL; Harris DL; Hollenberg PF
    Biochemistry; 2005 Mar; 44(10):3831-44. PubMed ID: 15751959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omega oxygenases: nonheme-iron enzymes and P450 cytochromes.
    Coon MJ
    Biochem Biophys Res Commun; 2005 Dec; 338(1):378-85. PubMed ID: 16165094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxidizing intermediates in P450 catalysis: a case for multiple oxidants.
    Modi AR; Dawson JH
    Adv Exp Med Biol; 2015; 851():63-81. PubMed ID: 26002731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxylation by the hydroperoxy-iron species in cytochrome P450 enzymes.
    Chandrasena RE; Vatsis KP; Coon MJ; Hollenberg PF; Newcomb M
    J Am Chem Soc; 2004 Jan; 126(1):115-26. PubMed ID: 14709076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cumene hydroperoxide-supported demethylation reactions catalyzed by cytochrome P450 2B4 lacking the NH2-terminal sequence.
    Zhang Y; Pernecky SJ
    Biochem Biophys Res Commun; 1999 Apr; 258(1):32-8. PubMed ID: 10222230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is the bound substrate in nitric oxide synthase protonated or neutral and what is the active oxidant that performs substrate hydroxylation?
    de Visser SP; Tan LS
    J Am Chem Soc; 2008 Oct; 130(39):12961-74. PubMed ID: 18774806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel reversible inactivation of cytochrome P450 2E1 T303A by tert-butyl acetylene: the role of threonine 303 in proton delivery to the active site of cytochrome P450 2E1.
    Blobaum AL; Kent UM; Alworth WL; Hollenberg PF
    J Pharmacol Exp Ther; 2004 Jul; 310(1):281-90. PubMed ID: 14988423
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Features of the metabolism of various drugs involving cytochrome P-450 isoenzymes].
    Filimonova AA; Ziganshin AU; Ziganshina LE
    Eksp Klin Farmakol; 2007; 70(3):69-77. PubMed ID: 17650639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The monooxygenase, peroxidase, and peroxygenase properties of cytochrome P450.
    Hrycay EG; Bandiera SM
    Arch Biochem Biophys; 2012 Jun; 522(2):71-89. PubMed ID: 22266245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Electronic ground states of iron porphyrin and of the first species in the catalytic reaction cycle of cytochrome P450s.
    Groenhof AR; Swart M; Ehlers AW; Lammertsma K
    J Phys Chem A; 2005 Apr; 109(15):3411-7. PubMed ID: 16833677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Possible involvement of singlet oxygen species as multiple oxidants in p450 catalytic reactions.
    Yasui H; Hayashi S; Sakurai H
    Drug Metab Pharmacokinet; 2005 Feb; 20(1):1-13. PubMed ID: 15770070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-temperature rapid-scan detection of reactive intermediates in epoxidation reactions catalyzed by a new enzyme mimic of cytochrome p450.
    Hessenauer-Ilicheva N; Franke A; Meyer D; Woggon WD; van Eldik R
    J Am Chem Soc; 2007 Oct; 129(41):12473-9. PubMed ID: 17880072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions.
    Lin Y; Lu P; Tang C; Mei Q; Sandig G; Rodrigues AD; Rushmore TH; Shou M
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):368-74. PubMed ID: 11259318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kinetic studies of reactions of iron(IV)-oxo porphyrin radical cations with organic reductants.
    Pan Z; Zhang R; Newcomb M
    J Inorg Biochem; 2006 Apr; 100(4):524-32. PubMed ID: 16500709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twenty years of biochemistry of human P450s: purification, expression, mechanism, and relevance to drugs.
    Guengerich FP; Hosea NA; Parikh A; Bell-Parikh LC; Johnson WW; Gillam EM; Shimada T
    Drug Metab Dispos; 1998 Dec; 26(12):1175-8. PubMed ID: 9860923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of substrate on the spectral properties of oxyferrous wild-type and T252A cytochrome P450-CAM.
    Sono M; Perera R; Jin S; Makris TM; Sligar SG; Bryson TA; Dawson JH
    Arch Biochem Biophys; 2005 Apr; 436(1):40-9. PubMed ID: 15752707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3.
    van Vugt-Lussenburg BM; Damsten MC; Maasdijk DM; Vermeulen NP; Commandeur JN
    Biochem Biophys Res Commun; 2006 Aug; 346(3):810-8. PubMed ID: 16777067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the conserved threonine 309 in mechanism of oxidation by cytochrome P450 2D6.
    Keizers PH; Schraven LH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; van Dijk BR; Vermeulen NP; Commandeur JN
    Biochem Biophys Res Commun; 2005 Dec; 338(2):1065-74. PubMed ID: 16269134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
    Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
    Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity.
    Lewis DF; Ito Y
    Xenobiotica; 2009 Aug; 39(8):625-35. PubMed ID: 19514836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.